share_log

IBEX Analyst Ratings

Benzinga ·  Sep 14, 2023 05:55
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/14/2023 -0.83% RBC Capital $27 → $18 Downgrades Outperform → Sector Perform
06/07/2023 54.27% Baird $28 → $28 Maintains Outperform
05/19/2023 32.23% Piper Sandler $32 → $24 Maintains Overweight
05/18/2023 48.76% RBC Capital $30 → $27 Maintains Outperform
05/18/2023 54.27% Baird $32 → $28 Maintains Outperform
05/18/2023 26.72% Citigroup $30 → $23 Maintains Neutral
04/20/2023 76.31% Baird $32 → $32 Maintains Outperform
02/16/2023 76.31% Baird $30 → $32 Maintains Outperform
02/16/2023 65.29% RBC Capital $26 → $30 Maintains Outperform
02/16/2023 76.31% Credit Suisse $27 → $32 Maintains Buy
02/16/2023 76.31% Piper Sandler $29 → $32 Maintains Overweight
01/24/2023 65.29% Baird $26 → $30 Maintains Outperform
01/06/2023 59.78% Piper Sandler $27 → $29 Maintains Overweight
11/18/2022 43.25% Citigroup $18 → $26 Maintains Neutral
11/16/2022 48.76% Truist Securities $22 → $27 Maintains Buy
11/16/2022 43.25% RBC Capital $20 → $26 Maintains Outperform
11/16/2022 48.76% Piper Sandler $20 → $27 Maintains Overweight
09/26/2022 21.21% Truist Securities $26 → $22 Maintains Buy
09/26/2022 -0.83% Citigroup $20 → $18 Maintains Neutral
09/23/2022 10.19% RBC Capital $22 → $20 Maintains Outperform
09/23/2022 10.19% Piper Sandler $21 → $20 Maintains Overweight
07/19/2022 10.19% Citigroup $21 → $20 Downgrades Buy → Neutral
07/18/2022 15.7% Piper Sandler $17 → $21 Maintains Overweight
05/19/2022 -6.34% Piper Sandler $20 → $17 Maintains Overweight
02/17/2022 10.19% Piper Sandler $18 → $20 Maintains Overweight
01/13/2022 -0.83% Piper Sandler $21 → $18 Maintains Overweight
12/22/2021 10.19% Baird → $20 Maintains Outperform
11/24/2021 15.7% Citigroup $23 → $21 Maintains Buy
11/23/2021 21.21% RBC Capital $24 → $22 Maintains Outperform
11/23/2021 15.7% Piper Sandler $22 → $21 Maintains Overweight
10/26/2021 54.27% Baird → $28 Maintains Outperform
09/16/2021 26.72% Citigroup $29 → $23 Maintains Buy
09/15/2021 21.21% Piper Sandler $25 → $22 Maintains Overweight
12/11/2020 37.74% Piper Sandler $19 → $25 Maintains Overweight
11/20/2020 -0.83% Citigroup $22 → $18 Maintains Buy
11/17/2020 4.68% Piper Sandler $18 → $19 Maintains Overweight
09/25/2020 -0.83% Piper Sandler $20 → $18 Maintains Overweight
09/01/2020 21.21% Truist Securities → $22 Initiates Coverage On → Buy
09/01/2020 21.21% Citigroup → $22 Initiates Coverage On → Buy
09/01/2020 21.21% Baird → $22 Initiates Coverage On → Outperform
09/01/2020 26.72% RBC Capital → $23 Initiates Coverage On → Outperform
09/01/2020 10.19% Piper Sandler → $20 Initiates Coverage On → Overweight

What is the target price for IBEX (IBEX)?

The latest price target for IBEX (NASDAQ: IBEX) was reported by RBC Capital on September 14, 2023. The analyst firm set a price target for $18.00 expecting IBEX to fall to within 12 months (a possible -0.83% downside). 21 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for IBEX (IBEX)?

The latest analyst rating for IBEX (NASDAQ: IBEX) was provided by RBC Capital, and IBEX downgraded their sector perform rating.

When is the next analyst rating going to be posted or updated for IBEX (IBEX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IBEX, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IBEX was filed on September 14, 2023 so you should expect the next rating to be made available sometime around September 14, 2024.

Is the Analyst Rating IBEX (IBEX) correct?

While ratings are subjective and will change, the latest IBEX (IBEX) rating was a downgraded with a price target of $27.00 to $18.00. The current price IBEX (IBEX) is trading at is $18.15, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment